Ranibizumab And Bevacizumab Show Equivalent Effects On Visual Acuity In Patients With Neovascular AMD

Two of the most commonly used treatments for neovascular age-related macular degeneration (AMD), ranibizumab (Lucentis, Genentech), approved in 2006 by FDA, and the other commonly used 'off-label,' bevacizumab (Avastin, Genentech), resulted in similar improvements in visual acuity, according to a new randomized controlled trial published online in the New England Journal of Medicine.

Full Story →